133 related articles for article (PubMed ID: 35913421)
1. Comparison of ophthalmic loteprednol etabonate and prednisolone acetate effects on adrenocortical response to ACTH in dogs.
Kline KE; Walton SA; Specht AJ; Santoro D; Watson TJ; Eide ML; Opgenorth TA; Plummer CE
Vet Ophthalmol; 2022 Nov; 25(6):468-475. PubMed ID: 35913421
[TBL] [Abstract][Full Text] [Related]
2. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pressure response to loteprednol etabonate in known steroid responders.
Bartlett JD; Horwitz B; Laibovitz R; Howes JF
J Ocul Pharmacol; 1993; 9(2):157-65. PubMed ID: 8345288
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
5. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.
Howes J; Novack GD
J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541
[TBL] [Abstract][Full Text] [Related]
6. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
7. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
Vittitow JL; Williams JI
J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.
Beyazyıldız E; Acar U; Beyazyıldız Ö; Pınarlı FA; Albayrak A; Uğurlu N; Tiryaki M; Delibaşi T
J Ocul Pharmacol Ther; 2014 May; 30(4):306-12. PubMed ID: 24494746
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
10. Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function.
Roberts SM; Lavach JD; Macy DW; Severin GA
Am J Vet Res; 1984 Sep; 45(9):1711-4. PubMed ID: 6497127
[TBL] [Abstract][Full Text] [Related]
11. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
12. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
14. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
15. Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1.
Marlowe ZT; Cavet ME; Coffey MJ
Ophthalmol Ther; 2022 Feb; 11(1):435-441. PubMed ID: 34919207
[TBL] [Abstract][Full Text] [Related]
16. The impact of single-dose trazodone administration on plasma endogenous adrenocorticotropic hormone and serum cortisol concentrations in healthy dogs.
Brown M; Lee-Fowler T; Behrend EN; Grobman M
J Vet Intern Med; 2024; 38(1):130-134. PubMed ID: 37965773
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
[TBL] [Abstract][Full Text] [Related]
18. The effect of loteprednol suspension eye drops after corneal transplantation.
Chen Y; Wang X; Gao M; Gao R; Song L
BMC Ophthalmol; 2021 May; 21(1):234. PubMed ID: 34039301
[TBL] [Abstract][Full Text] [Related]
19. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
Amon M; Busin M
Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]